Month: March 2020

With close to half-million infections and the economy showing signs of the 2008 financial crisis, COVID-19 has impacted several industries. Government institutes and industry players have announced various steps to deal with the ongoing situation. In this article, we will highlight the developments in the cell and gene therapy manufacturing industry amid the ongoing COVID-19

The ongoing COVID-19 crisis has put the pharmaceutical manufacturing supply chain under close scrutiny. The overdependence of the US on China and India to meet its API demand has been the talk of the town. However, with the number of infected cases in the US surpassing that of China, the focus has shifted from discussing

In a recent press release, bluebird bio, one of the leading gene therapy companies, announced that COVID-19 has delayed the EU launch and US filing of the company’s gene therapy candidate Zynteglo (LentiGlobin). The company now expects to dose the first commercial patient with Zynteglo in Germany in the second half of 2020. Earlier, the company had

As per a recent article published in Financial Times, Sanofi has warned that Europe lacks the coronavirus preventive vaccines market capacity to cope with the pandemic. Roots Analysis, in a recent report, has identified more than 40 covid19 vaccine that the currently being developed against the virus. To know more about the covid vaccines under

The ongoing COVID-19 pandemic has been nothing short of a nightmare. As the number of infected patients approaches 400,000, there is already a sense of worry looming across the industries. From disrupted supply chains to a prominent decrease in demand, the pharmaceutical industry is also facing its share of difficulties. A prominent shift towards the

To err is human, to rectify divine, this irony perhaps holds truer for cannabis than any other domain. After using cannabis in multiple forms for at least 10,000 years, a series of events, including spread of misinformation, anti-Mexican sentiment and fear led to the ban of nature a.k.a. cannabis. The US implemented Marijuana Tax Act

Over the past few years, therapeutic advancements in conventional treatment paradigms have led to an increase in survival among cancer patients. Recent developments in the field of immuno-oncology, such as the introduction of several liquid biopsy techniques, adoptive T-cell therapies, and immune checkpoint inhibitor based therapies, have demonstrated significant potential, and some of the aforementioned

Last week, during our weekly industry update sessions, our prime focus was to understand the recent innovations in the field of cell therapy manufacturing. We were also looking out for players that are driving these innovations. To start with, the first news that caught our attention was Novartis’ decision to sidestep Europe travel ban to

It is not very common to hear venture capital firms back competitors in the same week. It happened yesterday with Nurix announcing a USD 120 million backing yesterday, immediately after Kymera had grabbed an almost similar amount earlier this week. This does tell us something about the field of Targeted Protein Degradation! Read on. How

Targeted protein degradation (TPD), as a mechanism to target previously untreatable conditions, was one of the key highlights of the year 2019. In an article published late last year titled targeted protein degradation market, we discussed, in detail, the epic rise in the popularity of TPD. What is TPD? TPD is an emerging modality that

The interest in the trillions of human microbiome present in the human body has attracted a lot of research effort in the microbiome domain. The first such effort at a large scale was The Human Microbiome Project, conducted by the National Institutes of Health in the United States, which characterized the microbial communities at five

Roots Analysis has actively tracked the developments in the field of cell therapy and gene therapies. The team has focused on identifying the key challenges that are hampering the growth of these revolutionary therapies. To identify the challenges, the team has interviewed several stakeholders involved in cell therapy development and manufacturing. In addition, a recent

A lot has happened. And that too in a short span of time. A few weeks ago, everyone outside China was worried about the quarantined cruise ships. No one at that stage would have thought that, just in a few days, the virus may be knocking at the doorsteps. Now there is fear and it

So, another round of the World ADC (Antibody Drug Conjugates) just concluded. With a stellar line up that included Alain Beck from Pierre Fabre, Thorsten Sperber from Immunomedics, Nicholas Choong form Seattle Genetics, Rakesh Dixit from BioNavigen, Trevor Hallam from Sutro Bio and many other eminent personalities, the event did live up to its expectations.